Heartcore Capital

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Grandhood is a Danish investment management firm established in 2016, headquartered in Copenhagen. The company specializes in retirement planning and pension services, aiming to modernize the traditionally stagnant workplace pension industry through digital innovation. Grandhood offers an online platform that enables employers to provide pensions to their employees, along with voluntary health insurance and other benefits. The platform facilitates digital onboarding and provides advisory services at a competitive cost, ensuring swift customer support. Grandhood continually updates its product to adapt to evolving consumer needs, targeting companies embracing digital solutions for workplace pension management.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Mofibo, founded in Copenhagen in 2013, is one of the pioneering book subscription services globally. The company provides e-books through a proprietary platform that operates on a monthly subscription model, allowing consumers to access a diverse range of titles. Currently active in three countries, Mofibo plans to expand its reach into additional markets within the next year. With a focus on transforming the reading experience, Mofibo employs a data-driven and customer-centric approach to enhance how millions of people interact with books.

Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.

Adenium Biotech ApS is a Copenhagen-based biopharmaceutical company founded in 2011, specializing in the development and commercialization of novel antibiotics aimed at treating multi-drug resistant bacterial infections. The company focuses on addressing hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Its lead product, Arenicin, is a 21-amino acid antimicrobial peptide derived from the lugworm, demonstrating strong efficacy against Gram-negative pathogens while maintaining a broad therapeutic window. Adenium Biotech operates as a semi-virtual company, relying on a small team of experts supported by an international scientific advisory board to advance its clinical development programs toward regulatory approval.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.